ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Mark Barok, Vadim Le Joncour, Ana Martins, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalCancer Letters
Pages (from-to)156-163
Number of pages8
Publication statusPublished - 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Human epidermal growth factor receptor 2
  • T-DM1
  • Xenograft
  • Apoptosis
  • Drug resistance
  • PLUS
  • HER2
  • 3122 Cancers

Cite this